Zobrazeno 1 - 10
of 225
pro vyhledávání: '"Dong-Seok Yim"'
Autor:
Nirmal Rajasekaran, Hun Soon Jung, Soo Hyeon Bae, Chaithanya Chelakkot, Sungyoul Hong, Jong-Sun Choi, Dong-Seok Yim, Yu-Kyoung Oh, Yoon-La Choi, Young Kee Shin
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 10, Pp 735-749 (2017)
Toxicity and resistance remain major challenges for advanced or recurrent cervical cancer therapies, as treatment requires high doses of chemotherapeutic agents. Restoration of TP53 and hypophosphorylated-retinoblastoma (pRB) proteins by human papill
Externí odkaz:
https://doaj.org/article/c2fa6c0b77124668958555288e269051
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
The Comprehensive in vitro Proarrhythmia Assay (CiPA) project suggested the torsade metric score (TMS) which requires substantial computing resources as a useful biomarker to predict proarrhythmic risk from human ether-à-go-go–related gene (hERG)
Externí odkaz:
https://doaj.org/article/576fa38fe6a0420b8072ddc77811208b
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
The proarrhythmic risk is a major concern in drug development. The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative has proposed the JTpeak interval on electrocardiograms (ECGs) and qNet, an in silico metric, as new biomarkers that may ov
Externí odkaz:
https://doaj.org/article/91c831276633438188328453683ca847
Publikováno v:
Pharmaceutics, Vol 12, Iss 6, p 573 (2020)
CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor that is being developed for dyslipidemia. Even though CKD-519 has shown potent CETP inhibition, the exposure of CKD-519 was highly varied, depending on food and dos
Externí odkaz:
https://doaj.org/article/7743e6564faa4ee493a69302d51e5e4c
Publikováno v:
Pharmaceutics, Vol 11, Iss 7, p 336 (2019)
CKD519, a selective inhibitor of cholesteryl ester transfer protein(CETP), is undergoing development as an oral agent for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. The aim of this study was to predict the appropriate eff
Externí odkaz:
https://doaj.org/article/1a5302f7a2ed4f95a613b8550172d346
Autor:
Soo Hyeon Bae, Dong-Seok Yim, Hyemi Lee, Ae-Ryoung Park, Ji-Eun Kwon, Hirata Sumiko, Seunghoon Han
Publikováno v:
Pharmaceutics, Vol 11, Iss 5, p 224 (2019)
The population pharmacokinetic (PK) parameters that are implemented in therapeutic drug management (TDM) software were generally obtained from a Western population and might not be adequate for PK prediction with a Korean population. This study aimed
Externí odkaz:
https://doaj.org/article/44be5cfeb4964220936bbc00d344051d
Publikováno v:
Translational & Clinical Pharmacology. Mar2022, Vol. 30 Issue 1, p1-12. 12p.
Autor:
Filip Janku, Seung-Hoon Beom, Yong Wha Moon, Tae Won Kim, Young G. Shin, Dong-Seok Yim, Gun Min Kim, Hyo Song Kim, Sun Young Kim, Jae-Ho Cheong, Young Woo Lee, Barb Geiger, Sanghee Yoo, Archie Thurston, Dean Welsch, Marc S. Rudoltz, Sun Young Rha
Publikováno v:
Investigational New Drugs. 40:1001-1010
Preclinical models suggest anticancer activity of IM156, a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS). This first-in-human dose-escalation study enrolled patients with refractory advanced solid tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d67ffd5f66282c39467ad74e60eabcf9
https://doi.org/10.1007/s10637-022-01277-9
https://doi.org/10.1007/s10637-022-01277-9
Publikováno v:
Translational & Clinical Pharmacology. Jun2021, Vol. 29 Issue 2, p78-87. 10p.
Autor:
Dong-Seok Yim1,2 yimds@catholic.ac.kr, Suein Choi1,2
Publikováno v:
Translational & Clinical Pharmacology. Dec2020, Vol. 28 Issue 4, p169-174. 6p.